SNBL USA appoints vp of business development

Mark Crane takes overall responsibility for marketing, sales and business development

SNBL USA, a provider of preclinical services, has announced the arrival of Mark Crane as vice president of business development.

Crane takes responsibility for the company’s marketing, sales and business development efforts. He joins SNBL USA from Ricerca Biosciences where he was vice president of global sales and marketing.

Crane has held similar positions at Bridge Pharmaceutical (formerly GeneLogic), Quest Pharmaceutical Services, and MDS Pharma Services.

SNBL USA is a subsidiary of Shin Nippon Biomedical Laboratories (SNBL), one of the largest CROs in Japan.

You may also like

Research & Development

PPD and SNBL form JV to provide clinical development services in Japan

Will combine PPD's clinical development operations in Japan with SNBL's clinical research division
Research & Development

N4 Pharma and SRI to target and treat previously unreachable human cells

The companies will collaborate to perform research to conjugate SRI’s MGS system to Nuvec to increase intracellular delivery to specific target cells.
Research & Development

Owlstone Medical bags $6.5m to optimise infectious disease diagnostic tool

The Bill & Melinda Gates Foundation has funded the bolstering of the Breath Biopsy platform, as well as research into breath biomarkers in tuberculosis (TB) and HIV
Research & Development

New automated tissue dissociation systems

Introducing the new Singulator series (100 and 200)
Manufacturing

Memel Biotech and Therabest collaborate to develop exosome-based cell therapies

The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Research & Development

Fasenra for EGPA: addressing unmet needs

Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Research & Development

Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates

The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Subscribe now